Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Luiza Lara Gadotti"'
Autor:
Marcello Moro Queiroz, Karina Perez Sacardo, Mauricio Fernando Ribeiro, Luiza Lara Gadotti, Rodrigo Saddi, Leandro Jonata de Carvalho Oliveira, Rudinei Diogo Marques Linck, Marcelo Rocha de Souza Cruz, Romualdo Barroso-Sousa, Marina Sahade, Tatiana Strava Correa, Max Senna Mano, Daniele Assad Suzuki, Andrea Kazumi Shimada, Artur Katz
Publikováno v:
Cancer Treatment and Research Communications, Vol 35, Iss , Pp 100683- (2023)
Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have been recently developed and introduced into clinical practice. Methods: We retrospectively analyzed data from patients with confirmed HR+/HER2 metastatic breast cancer treated with hor
Externí odkaz:
https://doaj.org/article/f00841e7cf3c4c4fa3e29cdc2d34613b
Autor:
Maurício Fernando Silva Almeida Ribeiro, Luiza Lara Gadotti, Karina Perez Sacardo, Carlos Diego Holanda Lopes, Rodrigo Saddi, João Victor Machado Alessi, Mariana Petaccia de Macedo, Ellen Caroline Toledo do Nascimento, Leonardo de Abreu Testagrossa, Artur Katz
Publikováno v:
SAGE Open Medical Case Reports, Vol 10 (2022)
Chromosomal rearrangements involving the c-ros oncogene 1 ( ROS1 ) gene define a subset of non-small cell lung cancers highly sensitive to small-molecule tyrosine kinase inhibitors. However, little is known about the impact of different fusion partne
Externí odkaz:
https://doaj.org/article/28466b5038404de88eabd4d79f59b59e
Autor:
Ellen C. T. Nascimento, David E. Uip, Cesar Martins da Costa, Fernando Ganem, Maria C. Seiwald, Celso Arrais-Rodrigues, Luiza Lara Gadotti, Rodrigo Ramella Munhoz, Alessandra Corte Real Salgues
Publikováno v:
Journal of Medical Case Reports, Vol 15, Iss 1, Pp 1-5 (2021)
Journal of Medical Case Reports
Journal of Medical Case Reports
BackgroundHemophagocytic lymphohistiocytosis is a rare, potentially fatal syndrome of immune hyperactivation. Here we describe a ganglionar tuberculosis evolving to hemophagocytic lymphohistiocytosis following adjuvant immunotherapy in a melanoma pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d2f92e90dcd96874a44eb4f11cb1264
https://doaj.org/article/d03aa67bf7b54796a20eaae52302b281
https://doaj.org/article/d03aa67bf7b54796a20eaae52302b281
Autor:
Felipe Sales Nogueira Amorim Canedo, Maurício Fernando Silva Almeida Ribeiro, Joao Victor Machado Alessi, Luiza Lara Gadotti, Leonardo de Abreu Testagrossa, Artur Katz, Karina Perez Sacardo, Rodrigo Saddi
Publikováno v:
Clinical Lung Cancer. 22:e481-e486
Introduction It is widely accepted that detecting anaplastic lymphoma kinase (ALK) gene rearrangements is an important step for selecting effective therapies for patients with advanced non-small cell lung cancer (NSCLC). Alectinib is a potent and hig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe6540d52610a51662999a54b7d1899e
https://doi.org/10.1016/j.cllc.2020.06.021
https://doi.org/10.1016/j.cllc.2020.06.021
Autor:
Maurício Fernando Silva Almeida Ribeiro, Luiza Lara Gadotti, Karina Perez Sacardo, Carlos Diego Holanda Lopes, Rodrigo Saddi, João Victor Machado Alessi, Mariana Petaccia de Macedo, Ellen Caroline Toledo do Nascimento, Leonardo de Abreu Testagrossa, Artur Katz
Publikováno v:
SAGE Open Medical Case Reports. 10:2050313X2211004
Chromosomal rearrangements involving the c-ros oncogene 1 ( ROS1) gene define a subset of non-small cell lung cancers highly sensitive to small-molecule tyrosine kinase inhibitors. However, little is known about the impact of different fusion partner
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::87e43ce09ba9cf3f2ff3941acab79b36
https://doi.org/10.1177/2050313x221100407
https://doi.org/10.1177/2050313x221100407
Autor:
Carlos Diego Holanda Lopes, Artur Katz, Maurício Fernando Silva Almeida Ribeiro, Fabiane Marson, Karina Pinheiro, Joao Victor Machado Alessi, Rodrigo Saddi, Luiza Lara Gadotti
Publikováno v:
Journal of Clinical Oncology. 39:e18563-e18563
e18563 Background: Phase III clinical trials (PIIICT) constitute the cornerstone of the progress and development of new therapeutic strategies. However, their complexity and costs in a scenario of limited funding sources impose important limitations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83479d4b35c31c7737f644fe449c7791
https://doi.org/10.1200/jco.2021.39.15_suppl.e18563
https://doi.org/10.1200/jco.2021.39.15_suppl.e18563